| 代码 | 名称 | 主力净流入 (元) | 主力净占比 游资净流入 (元) | | | 游资净占比 散户净流入 (元) 散户净占比 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 300896 爱美客 | | 1776.60万 | 1.94% | -2191.86万 | -2.40% | 415.27万 | 0.45% | | 000615 | *ST美谷 | -180.80万 | -4.31% | -46.08万 | -1.10% | 226.88万 | 5.41% | | 688363 华熙生物 | | -1004.52万 | -2.44% | 420.82万 | 1.02% | 583.70万 | 1.42% | | 920982 锦波生物 | | -4352.79万 | -13.09% | -1671.41万 | -5.03% | -216.91万 | -0.65% | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。 | 代码 | 名称 | 收盘价 | 涨跌幅 ...

Investment Rating - The industry maintains a "Recommended" rating, with a focus on service consumption, beauty care, IP derivatives, and new consumption sectors such as gold and jewelry [5][28]. Core Insights - The report highlights a significant increase in the retail sales of cosmetics in China, reaching 822.53 billion yuan in 2025, representing a year-on-year growth of 6.18%. Online retail sales grew by 9.36%, accounting for 56.06% of total sales, while offline sales increased by 2.38% [3][25]. - The report notes that during the New Year's holiday, domestic travel reached 142 million trips, with total spending of 84.79 billion yuan, indicating strong consumer demand in the travel sector [4][26]. - The duty-free shopping market in Hainan saw a remarkable start to the year, with total sales amounting to 1.21 billion yuan from January 1 to 7, marking year-on-year increases of 88%, 30.3%, and 38.3% in sales amount, number of items, and number of visitors, respectively [27]. Summary by Sections Market Performance - From January 5 to January 9, 2026, the commerce retail, social services, and beauty care sectors increased by 4.23%, 4.71%, and 2.55%, respectively, ranking 15th, 14th, and 22nd among 31 primary industries. The Shanghai Composite Index rose by 3.82%, and the Shenzhen Component Index increased by 4.40% [15][18]. Key Industry Data and News - The Consumer Price Index (CPI) in December 2025 rose by 0.8% year-on-year, with core CPI (excluding food and energy) increasing by 1.2%. The overall CPI for 2025 remained flat compared to the previous year [3][25]. - The report discusses various developments in the beauty care sector, including the approval of a new botulinum toxin product by Ai Meike and the successful quality inspection of a long-acting botulinum toxin product by Furu Medical Technology [3][25][26]. Investment Recommendations - The report emphasizes a focus on service consumption and highlights specific companies for investment, including Ruoyu Chen, Maogeping, Shangmei Co., Pop Mart, Chaohongji, and Laopu Gold [5][28].

Core Viewpoint - The report from CITIC Securities indicates a gradual recovery in high-end consumption in China since Q3 2025, driven by the wealth effect from rising stock markets, with positive signs from international luxury brands and high-end retail properties [1] Group 1: Recovery Indicators - International luxury brands have shown signs of recovery since Q2 2025, with revenue growth returning in the Asia-Pacific region by Q3 2025 [2] - High-end retail properties in China began to recover at the end of 2024 and early 2025, with improved occupancy rates and sales, particularly in top luxury malls [2] - The global luxury market also entered a recovery phase starting Q3 2025 [2] Group 2: Investment Opportunities in High-End Consumption - The recovery of high-end consumption is influenced by factors such as the proportion of VIC (Very Important Customer) groups, the sequence of consumption based on wealth increase, the elasticity of supply, and consumption trends [3] - Categories with strong initial demand, driven by social status and identity needs, are expected to recover first, while categories with a high proportion of VIC customers and good supply conditions will show more sustained growth [3] - The fastest-growing segments in the luxury market from 2019 to 2025 include luxury cruises, private jets, high-end dining, personal luxury goods, luxury hotels, and high-end home goods [3] Group 3: Recommended Investment Targets - The report recommends focusing on luxury jewelry and leather goods, high-end domestic beauty products, and high-end outdoor sports [4] - Specific companies to watch include gold and jewelry brands like Lao Pu Gold and Chow Tai Fook, beauty brands like Mao Ge Ping, and sportswear brands like Anta Sports [4] - Other areas of interest include high-end commercial real estate, high-end residential real estate, gaming, private aviation, high-end tourism and dining, and premium liquor [4]

证券之星消息，1月12日医疗美容板块较上一交易日上涨0.4%，爱美客领涨。当日上证指数报收于 4165.29，上涨1.09%。深证成指报收于14366.91，上涨1.75%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | | | 主力净流入（元） 主力净占比 游资净流入（元） 游资净占比 散户净流入 (元) 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 000615 *ST美谷 | | -741.90万 | -14.47% | 221.67万 | 4.32% | 520.22万 | 10.15% | | 688363 华熙生物 | | -888.66万 | -3.25% | 140.49万 | 0.51% | 748.18万 | 2.74% | | 300896 | 爱美客 | -3419.73万 | -5.06% | 2238.97万 | 3.31% | 1180.76万 | 1.75% | | 920982 锦波生物 | | -3955.68万 | -14.39% | -710.72万 | -2.59% | 33. ...

Core Insights - The approval of the botulinum toxin product by Aimeike enhances the company's aesthetic medicine product line, filling a gap in its offerings [1] - The combination of this new product with existing offerings allows the company to provide more comprehensive solutions to customers, thereby strengthening its core competitiveness [1] - The aesthetic medicine consumption penetration rate still has significant room for growth, indicating potential for future expansion [1] Product Development - Aimeike has several products in development, including those for weight management and submental fat, which will further enrich its aesthetic medicine product pipeline upon launch [1] - The company is investing in self-research to create new product lines while also pursuing external acquisitions to enhance its product offerings [1] Financial Projections - The forecast for the company's net profit attributable to shareholders for 2025-2027 is set at 1.564 billion, 1.794 billion, and 2.099 billion yuan, respectively [1] - Corresponding price-to-earnings ratios (PE) are projected to be 28.2, 24.6, and 21 times for the same period [1] - The company maintains an "outperform the market" rating based on these projections [1]

Macroeconomic Insights - December CPI year-on-year growth expanded, primarily due to a low base and rising food prices[8] - PPI year-on-year decline narrowed, influenced by rising non-ferrous metal prices and the ongoing effects of "anti-involution" policies[8] - The price environment may continue to improve in 2026, with PPI supported by deepening "anti-involution" policies and tightening competition for key minerals[8] Market Trends - In December, the top 100 real estate companies achieved a total sales amount of CNY 341.5 billion, a month-on-month increase of 39.7%[33] - For the full year 2025, the cumulative sales amount for the top 100 real estate companies was CNY 3.36 trillion, a year-on-year decrease of 19.8%[33] - The new stock market saw 18 new listings in December, raising over CNY 30 billion, with average first-day gains of 214% for the main board and 296% for the dual innovation board[18] Industry Performance - The credit bond issuance volume increased seasonally, with a total of 332 bonds issued, amounting to CNY 312.27 billion, a week-on-week increase of 306%[22] - The domestic electrolytic aluminum price reached CNY 23,300 per ton, the highest since March 2022, with the aluminum-to-copper price ratio hitting a 20-year high[42] - The solid-state battery industry is entering a new phase of industrialization, with expectations for mass production by 2026-2027[47]

Investment Rating - The report rates the industry as "Outperforming the Market" [4] Core Insights - The probiotic market in China is expected to exceed 140 billion CNY by 2025, with a CAGR of 12.4% from 2019 to 2024 [11][12] - The second-generation probiotics, such as AKK strains, show significant advantages over first-generation probiotics, which are primarily preventive and transient [12][13] - The competitive landscape indicates that leading brands are facing pressure, while second and third-tier brands are rising, particularly through online channels [15][20] Summary by Sections Probiotic Market Overview - The C-end probiotic market in China is projected to grow from 647.7 billion CNY in 2018 to 1188.5 billion CNY in 2023, with a CAGR of 12.4% [11] - The gastrointestinal probiotic market is expected to reach 310 billion CNY by 2024, with a CAGR of 12% from 2019 to 2024 [11] Competitive Landscape - Leading brands like WonderLab and Life Space have seen a slight decline in market share, with WonderLab's GMV on Tmall and Douyin at 1.36 billion CNY in 2025, down 4.5% year-on-year [15] - Second and third-tier brands, such as Jiangzhong and Purmeo, have gained market share, increasing by over 2% [15] - The product offerings are evolving from basic probiotics to "probiotic+" series, indicating a shift towards more complex formulations [20] Investment Recommendations - The report recommends companies with strong organizational structures and management capabilities in the beauty care sector, such as Maogeping and Shangmei [28] - In the gold and jewelry sector, it suggests focusing on brands with strong pricing power and craftsmanship, recommending Laopu Gold and Chaohongji [28] - For the cross-border e-commerce sector, it highlights the potential of companies like Xiaoshangpin City and Jiaodian Technology due to easing trade conflicts and AI integration [28]

Investment Rating - The report indicates that the cosmetics and medical beauty sector is currently underperforming compared to the market, with the Shenwan Beauty Care Index rising by 2.6% from December 31, 2025, to January 9, 2026, which is lower than the overall market performance [1][2]. Core Insights - 毛戈平 has initiated an international strategic partnership with L Catterton, a leading global consumer investment firm, focusing on global market expansion, acquisitions, strategic investments, capital structure optimization, and talent introduction [1][6][17]. - The approval of products such as 爱美客's botulinum toxin and 奇璞生物's collagen implant signifies ongoing advancements in the medical beauty supply chain, enhancing competitive diversity for 2026 [1][6][18][19]. - The report highlights the robust foundation of 壹网壹创's e-commerce operations, leveraging AI to enhance performance and expand its market reach, particularly in the consumer goods sector [1][7][8][10]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown weaker performance compared to the market, with specific indices underperforming against the Shenwan A Index [2][4]. - The top-performing stocks in the sector include 力合科创 (+14.7%), 毛戈平 (+8.6%), and 水羊股份 (+7.6%), while the underperformers include 嘉亨家化 (-3.9%) and 百亚股份 (-2.8%) [2][5]. Recent Developments - 毛戈平's strategic collaboration with L Catterton aims to enhance its brand's presence in high-end retail channels globally and establish a joint investment fund focused on premium beauty products [1][6][17]. - The approval of 爱美客's botulinum toxin and 奇璞生物's collagen implant reflects a significant push in the medical beauty equipment supply chain, contributing to competitive advantages in the upcoming year [1][6][18][19]. E-commerce Insights - 壹网壹创's e-commerce operations are well-established, with a comprehensive coverage of consumer goods categories and a strong partnership with Alibaba, which is expected to drive revenue growth through AI integration [1][7][8][10]. - The e-commerce sector is witnessing a resurgence in attention, with Alibaba's platform traffic rebounding, indicating a potential recovery in the performance of e-commerce operations [1][8][10]. Market Data - The report notes that the retail sales of cosmetics in China for November 2025 grew by 6.1%, supported by promotional events like Double 11, indicating a robust recovery in consumer spending [13][15]. - The overall retail sales of consumer goods in China reached 45.6 trillion yuan in the first eleven months of 2025, with a year-on-year growth of 4.0% [13][15].

行 业 及 产 业 美容护理 2026 年 01 月 11 日 行 业 研 究 / 行 业 点 评 相关研究 证 券 研 究 报 告 证券分析师 王立平 A0230511040052 wanglp@swsresearch.com 王盼 A0230523120001 wangpan@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 联系人 王立平 A0230511040052 wanglp@swsresearch.com 毛戈平开启国际化战略合作，医美药械供给端持续发力 看好 ——化妆品医美行业周报 20250111 本期投资提示： 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 - ⚫ 本阶段化妆品医美板块表现弱于市场。2025 年 12 月 31 日至 2026 年 1 月 9 日期间， 申万美容护理指数上涨 2.6%，表现弱于市场。其中，申万化妆品指数上涨 2.3%，弱于 申万 A 指 2.8pct；申万个护用品指数上涨 0.8%，弱于申万 A 指数 4.4pct。 ⚫ 周观点：毛戈平开启国际 ...

Group 1 - The core viewpoint of the article is that Guosen Securities has given a "better than market" rating to Aimeike (300896.SZ) based on recent developments in its product pipeline and market potential [1] - Aimeike's exclusive distribution of Huons BioPharma's injectable botulinum toxin product has received regulatory approval for sale in China, including Hong Kong and Macau, filling a gap in its product line [1] - The company is expected to enhance its core competitiveness by offering comprehensive solutions through the combination of new and existing products, with ongoing research and development in weight management and submental fat products [1] Group 2 - The medical aesthetics consumption penetration rate still has significant room for improvement, indicating potential growth opportunities for the industry [1] - Aimeike is investing in self-research to develop new product lines while also pursuing mergers and acquisitions to enrich its product pipeline and expand international business [1] - The company’s performance growth is supported by these strategies, although there are potential risks related to project progress and market competition [1]